Trial Profile
A Study to Evaluate the Efficacy of Bortezomib as Add on to a Standard Regimen of Intravenous Methylprednisolone (IVMP), Intravenous Immunoglobulins (IVIG) and Therapeutic Plasmapheresis (PLEX) in Patients with Biopsy Proven Antibody Mediated Rejection (ABMR) Following Renal Transplant
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Dec 2015
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Immunoglobulins (Primary) ; Methylprednisolone (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 17 Dec 2015 New trial record